Publikation: Immunoproteasome inhibition attenuates experimental psoriasis
Dateien
Datum
Autor:innen
Herausgeber:innen
ISSN der Zeitschrift
Electronic ISSN
ISBN
Bibliografische Daten
Verlag
Schriftenreihe
Auflagebezeichnung
URI (zitierfähiger Link)
DOI (zitierfähiger Link)
Internationale Patentnummer
Link zur Lizenz
Angaben zur Forschungsförderung
Projekt
Open Access-Veröffentlichung
Sammlungen
Core Facility der Universität Konstanz
Titel in einer weiteren Sprache
Publikationstyp
Publikationsstatus
Erschienen in
Zusammenfassung
Introduction: Psoriasis is an autoimmune skin disease associated with multiple comorbidities. The immunoproteasome is a special form of the proteasome expressed in cells of hematopoietic origin.
Methods: The therapeutic use of ONX 0914, a selective inhibitor of the immunoproteasome, was investigated in Card14ΔE138+/- mice, which spontaneously develop psoriasis-like symptoms, and in the imiquimod murine model.
Results: In both models, treatment with ONX 0914 significantly reduced skin thickness, inflammation scores, and pathological lesions in the analyzed skin tissue. Furthermore, immunoproteasome inhibition normalized the expression of several pro-inflammatory genes in the ear and significantly reduced the inflammatory infiltrate, accompanied by a significant alteration in the αβ+ and γδ+ T cell subsets.
Discussion: ONX 0914 ameliorated psoriasis-like symptoms in two different murine psoriasis models, which supports the use of immunoproteasome inhibitors as a therapeutic treatment in psoriasis.
Zusammenfassung in einer weiteren Sprache
Fachgebiet (DDC)
Schlagwörter
Konferenz
Rezension
Zitieren
ISO 690
DEL RIO OLIVA, Marta, Mark MELLETT, Michael BASLER, 2022. Immunoproteasome inhibition attenuates experimental psoriasis. In: Frontiers in Immunology. Frontiers Media. 2022, 13, 1075615. eISSN 1664-3224. Available under: doi: 10.3389/fimmu.2022.1075615BibTex
@article{DelRioOliva2022-12-14Immun-59567, year={2022}, doi={10.3389/fimmu.2022.1075615}, title={Immunoproteasome inhibition attenuates experimental psoriasis}, volume={13}, journal={Frontiers in Immunology}, author={Del Rio Oliva, Marta and Mellett, Mark and Basler, Michael}, note={German Research Foundation (DFG) grant GR 1517/27-1 and SFB969 project C01 Corrigendum: https://doi.org/10.3389/fimmu.2023.1335691 Article Number: 1075615} }
RDF
<rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:bibo="http://purl.org/ontology/bibo/" xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:void="http://rdfs.org/ns/void#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/59567"> <dcterms:abstract xml:lang="eng">Introduction: Psoriasis is an autoimmune skin disease associated with multiple comorbidities. The immunoproteasome is a special form of the proteasome expressed in cells of hematopoietic origin.<br /><br />Methods: The therapeutic use of ONX 0914, a selective inhibitor of the immunoproteasome, was investigated in Card14ΔE138<sup>+/-</sup> mice, which spontaneously develop psoriasis-like symptoms, and in the imiquimod murine model.<br /><br />Results: In both models, treatment with ONX 0914 significantly reduced skin thickness, inflammation scores, and pathological lesions in the analyzed skin tissue. Furthermore, immunoproteasome inhibition normalized the expression of several pro-inflammatory genes in the ear and significantly reduced the inflammatory infiltrate, accompanied by a significant alteration in the αβ<sup>+</sup> and γδ<sup>+</sup> T cell subsets.<br /><br />Discussion: ONX 0914 ameliorated psoriasis-like symptoms in two different murine psoriasis models, which supports the use of immunoproteasome inhibitors as a therapeutic treatment in psoriasis.</dcterms:abstract> <dc:creator>Del Rio Oliva, Marta</dc:creator> <foaf:homepage rdf:resource="http://localhost:8080/"/> <dcterms:rights rdf:resource="http://creativecommons.org/licenses/by/4.0/"/> <dc:rights>Attribution 4.0 International</dc:rights> <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2022-12-20T10:11:38Z</dcterms:available> <dcterms:title>Immunoproteasome inhibition attenuates experimental psoriasis</dcterms:title> <dc:language>eng</dc:language> <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/> <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/> <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/> <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/59567"/> <dc:contributor>Del Rio Oliva, Marta</dc:contributor> <dcterms:issued>2022-12-14</dcterms:issued> <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2022-12-20T10:11:38Z</dc:date> <dc:contributor>Mellett, Mark</dc:contributor> <dc:creator>Basler, Michael</dc:creator> <dc:creator>Mellett, Mark</dc:creator> <dcterms:hasPart rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/59567/1/DelRioOliva_2-vuy7lolf6jkg8.pdf"/> <dspace:hasBitstream rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/59567/1/DelRioOliva_2-vuy7lolf6jkg8.pdf"/> <dc:contributor>Basler, Michael</dc:contributor> </rdf:Description> </rdf:RDF>